Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Photopharmacology describes the use of light to precisely deliver drug activity in space and time. Such approaches promise to improve drug specificity by reducing off-target effects. As a proof-of-concept, we have subjected the fourth generation photoswitchable sulfonylurea JB253 to comprehensive toxicology assessment, including mutagenicity and maximum/repeated tolerated dose studies, as well as in vivo testing in rodents. Here, we show that JB253 is well-tolerated with minimal mutagenicity and can be used to optically-control glucose homeostasis in anesthetized mice following delivery of blue light to the pancreas. These studies provide the first demonstration that photopharmacology may one day be applicable to the light-guided treatment of type 2 diabetes and other metabolic disease states in vivo in humans.

Original publication

DOI

10.1038/s41598-017-00397-0

Type

Journal article

Journal

Sci Rep

Publication Date

2017

Volume

7

Keywords

Animals Blood Glucose Diabetes Mellitus/*drug therapy Drug-Related Side Effects and Adverse Reactions Homeostasis Hypoglycemic Agents/*administration & dosage/adverse effects Mice Photosensitizing Agents/*administration & dosage/adverse effects Sulfonylurea Compounds/*administration & dosage/adverse effects Treatment Outcome